Oncoloxía médica
Servizo
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (94)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology
-
Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients’ healthcare in Spain
Clinical and Translational Oncology
-
Indicators to evaluate quality of care in head and neck cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology
-
Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology
Clinical and Translational Oncology
-
Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group
Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 171-177
2023
-
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2732-2748
-
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
Cancers, Vol. 15, Núm. 11
-
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 882-896
-
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 897-911
-
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119